CRDF ▼ -4.1% - Cardiff Oncology, Inc. $CRDF - Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement Cardiff Oncology shares fell 4.1% today following an announcement that the company amended its 2017 exclusive license agreement with Nerviano Medical Sciences. The amendment's specific terms were not detailed in the headline, leaving investors without clarity on whether the change expands or narrows the company's rights or financial obligations under the deal. 14-SEP-2026 08:32 AM ET